Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Lifecare AS ( (DE:LFC0) ) is now available.
Lifecare ASA has filed for regulatory approval to begin the first human clinical trial of its wireless CGM implant, marking a significant milestone in its clinical and commercial development strategy. The trial is expected to conclude by early Q4 2025, with a pivotal CE-mark trial planned for later this year and a commercial launch anticipated in 2027, aligning with the company’s strategic goals and operational plans.
More about Lifecare AS
Lifecare ASA is a medtech company specializing in the development of next-generation Continuous Glucose Monitoring (CGM) systems for diabetes management. The company focuses on using osmotic pressure as a sensing principle to monitor various body analytes, aiming to bring advanced CGM technology to both humans and pets.
Average Trading Volume: 27,893
Current Market Cap: NOK121.8M
For a thorough assessment of LFC0 stock, go to TipRanks’ Stock Analysis page.